reviewTop 1% cited
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
European Journal of Cancer · 2017 · Vol. 73 · pp. 1–8
Stefania Cuzzubbo✉(Hôpital Avicenne)F. Javeri(Assistance Publique – Hôpitaux de Paris)M Tissier(Hôpital Avicenne)A. Roumi(Assistance Publique – Hôpitaux de Paris)Ciprian Barlog(Université Sorbonne Paris Nord)Jennifer Doridam(Université Sorbonne Paris Nord)Célèste Lebbé(Université Paris Cité)Cathérine Belin(Hôpital Avicenne)Rénata Ursu(Hôpital Avicenne)Alain Carpentier(Hôpital Avicenne)
Cancer Immunotherapy and BiomarkersBrain Metastases and TreatmentLung Cancer Research StudiesMedicineIncidence (geometry)Adverse effectHeadachesInternal medicineClinical trialPediatricsSurgery
MeSH terms
Antibodies, MonoclonalAntineoplastic AgentsHumansImmunotherapyNeoplasmsNervous System DiseasesIncidenceMolecular Targeted TherapyCTLA-4 AntigenProgrammed Cell Death 1 Receptor
Citations
534
FWCI
22.72
field-weighted impact
References
96
Percentile
100%
vs. same field & year
Citations per year
Cited by
The evolution of immunotherapeutics: Mechanisms, milestones, and the path ahead
International Journal of Pharmacognosy and Clinical Research · 2025 · 0 citations
A review of cancer immunotherapy toxicity
CA A Cancer Journal for Clinicians · 2020 · 1,391 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 3,616 citations
References
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology · 2015 · 1,554 citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
The Lancet Oncology · 2014 · 1,480 citations
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
The Lancet Oncology · 2015 · 1,421 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology · 2014 · 2,198 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.